{"id":"W2921789044","doi":"10.1200/jco.2019.37.7_suppl.544","title":"Subgroup analysis from JAVELIN Renal 101: Outcomes for avelumab plus axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Renal cell carcinoma; Subgroup analysis; Axitinib; Sunitinib; Clinical endpoint; Temsirolimus; Progression-free survival; Discontinuation; Gastroenterology; Randomized controlled trial; Urology; Oncology; Confidence interval; Overall survival","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004212241,0.001052737,0.00324933,0.0006128679,0.0002307721,0.0009015021,0.0007584883,0.001073852,0.002911747],"category_scores_gemma":[0.003934792,0.0002917334,0.009335767,0.00057662,0.00031674,0.0006089427,0.0006846041,0.001511271,0.0002911507],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008338491,"about_ca_system_score_gemma":0.0009972759,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001034345,"about_ca_topic_score_gemma":0.002793282,"domain_scores_codex":[0.9975693,0.001291536,0.0003112488,0.0003668042,0.0002105479,0.0002505651],"domain_scores_gemma":[0.9981501,0.0008960559,0.0004062922,0.0001925306,0.00007198515,0.0002830556],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.8386443,0.0009226067,0.04827514,0.00230241,0.06098929,0.0003865602,0.0001649329,0.00266835,0.006432451,0.0002687567,0.004221901,0.03472329],"study_design_scores_gemma":[0.3703602,0.1332329,0.332258,0.0006033321,0.1318308,0.001128501,0.0007017147,0.01191364,0.005411399,0.003272771,0.009011094,0.0002756626],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9829289,0.01052419,0.0006274465,0.0006736016,0.0002669865,0.0006437824,0.003073384,0.00003851459,0.001223227],"genre_scores_gemma":[0.9953536,0.0008550247,0.0003594344,0.0003771882,0.000138199,0.0004513934,0.001892213,0.00001324843,0.0005596501],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004212241,"threshold_uncertainty_score":0.02227676,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1092919152384351,"score_gpt":0.4221614423895783,"score_spread":0.3128695271511432,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}